Hikma Pharmaceuticals (HIK)

Sector: Pharma and Biotech     Index: FTSE 250
-3.60%
-43.00p
1,150.00p
17:17 19/09/17
1,150.00p
17:17 19/09/17
DAILY VARIATION
-3.60%
-43.00p
VOLUME
660,462
REAL TIME BATS
1,150.00p
17:36 19/09/17
-3.69%
-44.00p
DATA
52 Week High
2,297.00p
52 Week Low
1,119.00p
Shares Issued
240.65m
Market Cap
£2,767.44m
RiskGrade
202
Beta
1.05
MENU

Hikma Pharmaceuticals Overview

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma’s operations are in the United States, the Middle East and North Africa Region and Europe.

slide to see more
Registrars:

Key Personnel

slide to see more
CFO: Khalid Nabilsi
Non-Executive Director: Ali Al-Husry, Pamela Kirby, Ronald L Goode, Michael Ashton, Jochen Gann, Pat Butler
Senior Independent Director: Robert Pickering
Chairman and CEO: Said Darwazah
Independent Non-Executive Director: John J. Castellani, Mary (Nina) Henderson
Company Secretary: Peter Speirs
Executive Vice Chairman: Mazen Darwazah

Contact Details

slide to see more
Address: 1 New Burlington Place, London,United Kingdom
Phone: +44 (0)20 7399 2760
Fax: +44 (0)20 7399 2761
Website: http://www.hikma.com
Email:

Listings

slide to see more
ISIN: GB00B0LCW083
Sector: Pharmaceuticals & Biotechnology
Main Indices: FTSE 250, FTSE-350, FTSE All-Share, FTSE All-Share